Evidence map›Paper›PMID 41176542›Full record

ArticleBlood cancer journal2025

Glofitamab combined with tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: a single-center pilot trial.

De Zhou, Wenjuan Yu, Mixue Xie, Ehsan Ghoushi, Xuelian Hu, Xin Huang, Juying Wei, Xingnong Ye, Xiaolong Zheng, Jie Jin and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

De Zhou *Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0002-3698-2750
Wenjuan Yu *Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mixue Xie *Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ehsan GhoushiZhejiang University School of Medicine, Hangzhou, China.
Xuelian HuDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xin HuangDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Juying WeiDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xingnong YeDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaolong ZhengDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jie JinDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0002-8166-9915
Wanzhuo XieDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. xiewanzhuo@zju.edu.cn.ORCID http://orcid.org/0000-0002-0966-5581
Hongyan TongDepartment of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. tonghongyan@zju.edu.cn.ORCID http://orcid.org/0000-0001-5603-4160

Funding

Zhejiang Province Public Welfare Technology Application Research Project (Public Welfare Technology Application Research Project of Zhejiang Province) No. LGF22H160040
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41176542
PMCPMC12579608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.